118 related articles for article (PubMed ID: 3450294)
1. In vitro and in vivo assessment of activity of new anilino-substituted analogues of amsacrine against Lewis lung carcinoma.
Rewcastle GW; Denny WA; Wilson WR; Baguley BC
Anticancer Drug Des; 1986 Nov; 1(3):215-22. PubMed ID: 3450294
[TBL] [Abstract][Full Text] [Related]
2. Amsacrine analogues with extended chromophores: DNA binding and anti-tumour activity.
Denny WA; Baguley BC
Anticancer Drug Des; 1987 Aug; 2(1):61-70. PubMed ID: 3449085
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
4. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
5. Steric constraints for DNA binding and biological activity in the amsacrine series.
Denny WA; Twigden SJ; Baguley BC
Anticancer Drug Des; 1986 Apr; 1(2):125-32. PubMed ID: 3450288
[TBL] [Abstract][Full Text] [Related]
6. Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of amsacrine.
Baguley BC; Wilson WR
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):607-13. PubMed ID: 3653185
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines.
Gamage SA; Figgitt DP; Wojcik SJ; Ralph RK; Ransijn A; Mauel J; Yardley V; Snowdon D; Croft SL; Denny WA
J Med Chem; 1997 Aug; 40(16):2634-42. PubMed ID: 9258370
[TBL] [Abstract][Full Text] [Related]
8. Relationship between the structure of analogues of amsacrine and their degree of cross-resistance to adriamycin-resistant P388 leukaemia cells.
Baguley BC; Finlay GJ
Eur J Cancer Clin Oncol; 1988 Feb; 24(2):205-10. PubMed ID: 3356208
[TBL] [Abstract][Full Text] [Related]
9. Derivatives of amsacrine: determinants required for high activity against Lewis lung carcinoma.
Baguley BC; Finlay GJ
J Natl Cancer Inst; 1988 Apr; 80(3):195-9. PubMed ID: 3346911
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
[TBL] [Abstract][Full Text] [Related]
11. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
12. Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity.
Atwell GJ; Rewcastle GW; Baguley BC; Denny WA
J Med Chem; 1987 Apr; 30(4):652-8. PubMed ID: 3560159
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
[TBL] [Abstract][Full Text] [Related]
14. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Spicer JA; Gamage SA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1997 Jun; 40(12):1919-29. PubMed ID: 9191970
[TBL] [Abstract][Full Text] [Related]
18. [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus].
René B; Fossé P; Khélifa T; Jacquemin-Sablon A; Bailly C
Bull Cancer; 1997 Oct; 84(10):941-8. PubMed ID: 9435795
[TBL] [Abstract][Full Text] [Related]
19. 'Minimal' DNA-intercalating agents as anti-tumour drugs: 2-styrylquinoline analogues of amsacrine.
Denny WA; Atwell GJ; Baguley BC
Anticancer Drug Des; 1987 Dec; 2(3):263-70. PubMed ID: 3449090
[TBL] [Abstract][Full Text] [Related]
20. Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity.
Bacherikov VA; Chou TC; Dong HJ; Zhang X; Chen CH; Lin YW; Tsai TJ; Lee RZ; Liu LF; Su TL
Bioorg Med Chem; 2005 Jun; 13(12):3993-4006. PubMed ID: 15911312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
